Sedona Invest has acquired Abiocom
The shareholders of Abiocom have sold the company to Sedona Invest.
Sedona Invest is a family office founded in 2020 dedicated to the well-being and organic industries.
Founded in 2007, Abiocom is specialized in design, development and distribution of organic well-being products. The company provides a wide range of more than 300 products from seven own brands and two other brands in exclusive distribution, covering five categories: food supplements, cosmetics, make-up, incense and eco-housing. Abiocom has a portfolio of over 1,700 active clients, including organic chains and independent stores.
Oaklins’ team in France acted as advisor to the shareholders of Sedona Invest in this transaction.
Talk to the deal team
Related deals
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more